|
|
CytoGenix, Inc. (CYGX) |
|
|
|
CEOCFO Current
Issue |
This is a printer friendly page! CytoGenix - going after diseases that they can approach with a topical delivery such as herpes and the human papaloma virus that causes cervical cancer
CytoGenix Inc. (OTC: CYGX) is a biopharmaceutical
company that develops and markets innovative products and services based on its
proprietary DNA expression technology. CytoGenix has products in pre-clinical development
including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company
owns a U.S. patent for its core DNA expression technology and has 40 international or U.S.
pending patent applications. Dr. Malcolm Skolnick, Chairman
and CEO of CytoGenix, commenting on how the Company selects which diseases to target tell
us, “The delivery being an important consideration, we have
chosen to go after diseases that we can approach with topical delivery; that is putting
our formulations onto skin or into cells that are available. For example, herpes because
it is a skin disease is a good target. The human papaloma virus, which causes cervical
cancer, is also a good target because we can approach that with a topical application. The
human RHINO virus, which causes colds, is also a good target because we can approach that
topically as well, by using an aerosol spray into the mucosal passages. The
anti-inflammatory that we are after is another topical target because it expresses itself
in skin and various types of dermatitis, abrasions and burns. We have chosen targets that
we know we can make our technology work, in conjunction with delivery that we know we can
achieve.” “Our idea to demonstrate the science for
a particular approach is very sound.” Offers Dr.
Skolnick, when asked what differentiates the CytoGenix business model from other
companies in its sector, “We will take that science through
cell cultures, tissue cultures, animal trials and into clinical trials, and then work hard
to find strategic partners who can take the product the rest of the way to market. We
expect to be able to make our primary revenue through licensing our technology in specific
fields. The other part of our model is to use our technology to do what is called
“target validations”, that is we can identify genes and the proteins that they
express. When down-regulating those genes, we can also identify the cell phenotypes that
are different without the particular protein. We have developed a variant of the
technology, which we call “screening library,” which allows us to screen for
millions of different type sequences that can have an affect on cells. We have also done
that in conjunction with a number of different approaches to see the affect on
cells.” Dr. Skolnick demonstrating that under his
leadership, the Company understands what it needs to do to succeed internationally states,
“We want to make sure that if our products are made and sold,
they are done so under the compliance of whatever country’s regulatory elements there
are. Certainly, that is going to b true inside the United States, and certainly, we want
that to be so in The People’s Republic of China or whatever other countries where we
expect to continue business. It will not do for us to go to the FDA and then have a record
to where we sold product without regulatory approval. The pressure to do that is enormous
because we have seen enough positive results from the use of our preparation, that people
are putting demands upon us.” Offering some thoughts on what investors should
look for when considering CytoGenix, “People should not invest
in our company unless they have the intent to put some effort into understanding our
technology, and then they should follow the way we are developing scientifically.”
Continues Dr. Skolnick, “I think
if people do that, they will recognize that we have an enormously broad platform that is
approachable. We have a business model that we think is beginning to work. We have been in
business with this technology for about four years, which is a short time for most
Biotechs. We think that in our next round of funding we will get enough money to get a
couple of our formulations into clinical trials. If we do, we will see success in our
licensing to larger corporations that will be able to take us the rest of the way through
the FDA. I advise people to look at our track-record, and look at our future plans to see
whether we keep our promises.” Left click below to: |
|
|
|
To view Releases highlight & left click on the company name!
|
|
